In the above-named article by Bhat SZ, Lim S, Sidhaye A, and Hamrahian AH (JCEM Case Reports. 2023, 1(5); doi: 10.1210/jcemcr/luad104), there were errors throughout the article.
In Table 2, the heading read: “Table 2. Clinical characteristics differentiating between type B insulin resistance syndrome, insulin autoimmune syndrome, and insulinoma.” In the corrected article, the heading reads: “Table 2. Clinical and biochemical characteristics differentiating between type B insulin resistance syndrome, insulin autoimmune syndrome, and insulinoma for patients presenting with hypoglycemia.”
In Table 2, in the “C-peptide level” row, under the “Type B insulin resistance syndrome” column, the three arrows were pointed upward: “↑/↑↑”. In the corrected article, the arrows are pointing downward: “↓/↓↓”.
In the Discussion section, in the fourth paragraph, the text read: “Other features differentiating hypoglycemia in TBIRS from insulinoma include much higher levels of insulin, C-peptide, and pro-insulin in TBIRS compared with insulinoma.” In the corrected article, the text now reads: “Hypoglycemia in TBIRS is associated with low levels of serum C-peptide compared with high or inappropriately normal C-peptide levels in patients with insulinomas. This is due to C-peptide being cleared by insulin-receptor-independent mechanisms. Our patient had elevated serum C-peptide during the hypoglycemic episode, possibly related to serum C-peptide not yet achieving a steady state.”
The article has been corrected online.